U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495956) titled 'cfMSC Therapy for Diabetes' on March 22.
Brief Summary: The purpose of this study is to assess the feasibility, safety and clinical efficacy of the novel clonal fetal mesenchymal stem cell (cfMSC) therapy in patients with type II diabetes mellitus.
Study Start Date: March 16
Study Type: INTERVENTIONAL
Condition:
Type II Diabetes Mellitus
Intervention:
BIOLOGICAL: cfMSC therapy for diabetes
Clonal fetal mesenchymal stem cells (cfMSCs) therapy for type II diabetes mellitus
Recruitment Status: RECRUITING
Sponsor: Shenzhen Geno-Immune Medical Institute
Disclaimer: Curated by HT Syndication....